KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome. PMID 40318055 · Br J Haematol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrative analysis of high-dimensional RCT and RWD subject to censoring and hidden confounding. PMID 40301269 · Lifetime Data Anal · 2025-Jul The record is an oncology, human, randomized Phase 3 trial with a survival (time-to-event) outcome, but it does not involve a drug-containing intervention (it compares surgical techniques: lobar vs. sublobar resection). Therefore, it is excluded.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neurostimulant Use for Rehabilitation and Recovery After Stroke: A Narrative Literature Review. PMID 40248871 · Stroke · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Rilzabrutinib for the Treatment of Immune Thrombocytopenia. PMID 40222822 · Eur J Haematol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. PMID 40212008 · Diabetes Obes Metab · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Contact X-ray brachytherapy in rectal cancer: A systematic review and meta-analysis. PMID 40174334 · Eur J Surg Oncol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of YJP-40 in Patients with Acute Bronchitis: A Randomized, Double-Blind, Parallel Group Study. PMID 40109035 · Tuberc Respir Dis (Seoul) · 2025-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). PMID 39986336 · Am Heart J · 2025-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical Trials. PMID 39947298 · J Allergy Clin Immunol Pract · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
NIFTy: near-infrared fluorescence (NIRF) imaging to prevent postsurgical hypoparathyroidism (PoSH) after thyroid surgery-a phase II/III pragmatic, multicentre randomised controlled trial protocol in patients undergoing a total or completion thyroidectomy. PMID 39890139 · BMJ Open · 2025-Jan-30 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. PMID 39887551 · Addiction · 2025-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. PMID 39883436 · JAMA · 2025-Jan-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
CRISPR-Based Therapy for Hereditary Angioedema. PMID 39445704 · N Engl J Med · 2025-Jan-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
TAD-SIE: sample size estimation for clinical randomized controlled trials using a Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator. PMID 39881374 · Trials · 2025-Jan-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane. PMID 39875951 · Cardiooncology · 2025-Jan-28 This is a protocol/design article for an ongoing Phase III randomized trial in oncology with a drug intervention. However, it reports no efficacy results. The primary endpoint (incidence of cardiac dysfunction) is a safety/toxicity endpoint, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required. Therefore, it is excluded as a protocol without results.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials. PMID 39871514 · Acta Oncol · 2025-Jan-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study). PMID 39865222 · BMC Cancer · 2025-Jan-27 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Analysis of Research Waste in Phase III/IV Randomized Controlled Trials of Botulinum Toxin Type A. PMID 39840849 · Dermatol Surg · 2025-Jan-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century. PMID 39570146 · Clin Exp Immunol · 2025-Jan-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. PMID 39662097 · Eur J Cancer · 2025-Jan-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma. PMID 39814865 · Sci Rep · 2025-Jan-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment. PMID 39809874 · NPJ Digit Med · 2025-Jan-14 The study is a randomized Phase III trial in oncology, but the intervention is non-drug (digital integrative medicine) and the endpoints are symptom/quality-of-life measures and healthcare utilization, not time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials. PMID 39825757 · J Crohns Colitis · 2025-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Obtaining personalized predictions from a randomized controlled trial on Alzheimer's disease. PMID 39799207 · Sci Rep · 2025-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Statistical methods in the analysis of multicentre HIV randomized controlled trials in the African region: a scoping review. PMID 39773382 · BMC Med Res Methodol · 2025-Jan-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Protocol digest of a phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery-hyperintense lesion on MRI for newly diagnosed supratentorial glioblastoma: JCOG2209 (FLAMINGO). PMID 39292165 · Jpn J Clin Oncol · 2025-Jan-08 The record is a protocol for a phase III randomized trial with a primary OS endpoint, but it lacks formal results and describes a surgical intervention, not a drug-containing one.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design. PMID 39719420 · J Am Heart Assoc · 2025-Jan-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Home high-flow therapy during recovery from severe chronic obstructive pulmonary disease (COPD) exacerbation: a mixed-methods feasibility randomised control trial. PMID 39762067 · BMJ Open Respir Res · 2025-Jan-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of hydrolyzed yeast on weanling pig growth performance, fecal dry matter, and stress-related blood antioxidant criteria. PMID 41002176 · J Anim Sci · 2025-Jan-04 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Supplemental effects of acidifier and encapsulated butyrate solely and combined in high canola meal diets for nursery pigs. PMID 40233213 · J Anim Sci · 2025-Jan-04 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring. PMID 39841472 · JAMA Netw Open · 2025-Jan-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 4 Figure · 18 Panel · risk visible
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. PMID 39752157 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. PMID 39570620 · JAMA Oncol · 2025-Jan-01 The trial is a Phase 1b study with a primary endpoint of pharmacokinetics and secondary endpoints of safety and response rates. It does not meet the required Phase III/IIIb or Phase II/III criteria, and lacks a time-to-event efficacy endpoint such as OS or PFS.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol for the Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Studies. PMID 39560771 · Pediatr Crit Care Med · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Perioperative systemic therapy, current paradigm and ongoing clinical trials in upper tract urothelial cancer. PMID 39444267 · Curr Opin Urol · 2025-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management. PMID 39400109 · Curr Opin Rheumatol · 2025-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue sarcoma. PMID 39292680 · Cancer · 2025-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Correction to "Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)". PMID 39291660 · Int J Cancer · 2025-Jan-01 The record is a published erratum for a Phase III trial. It does not contain original trial results or report a primary/key secondary time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer. PMID 39878268 · Int J Gynecol Cancer · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis. PMID 39877569 · BJUI Compass · 2025-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial. PMID 39866854 · EClinicalMedicine · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Scleroderma-Associated Autoantibodies on Clinical Outcome Assessments: Post Hoc Analysis From a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial of Tocilizumab in Scleroderma. PMID 39846245 · ACR Open Rheumatol · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A New Hope for the Patients of Non-Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use. PMID 39846038 · Health Sci Rep · 2025-Jan The record is a review article summarizing a Phase 3 trial for a non-oncology indication (NASH). The primary efficacy endpoints reported are histological (NASH resolution, fibrosis improvement), not time-to-event outcomes like OS or PFS. The article itself is a literature review, not an original report of a clinical trial. Therefore, it does not meet the required criteria for inclusion.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. PMID 39810771 · Kidney Int Rep · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis. PMID 39810768 · Kidney Int Rep · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children. PMID 39777610 · Dermatol Ther (Heidelb) · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Preoperative Physical Activity Improvement with the Use of Activity Trackers in Patients Undergoing Radical Cystectomy-A Bicentric, Open-label, Randomised Controlled Trial: A Clinical Study Protocol of the PreAct Trial. PMID 39758853 · Eur Urol Open Sci · 2025-Jan 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Genome analysis uncovers an inverse correlation between alterations in P21-activated kinases and patient survival across multiple cancer types. PMID 39756822 · Physiol Rep · 2025-Jan The record describes a biomarker analysis of genomic data aggregated from multiple publicly available clinical trial datasets. It does not present the primary efficacy results of a single randomized trial with a drug intervention and a time-to-event endpoint.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Informative censoring in externally controlled clinical trials: a potential source of bias. PMID 39754980 · ESMO Open · 2025-Jan The record describes a methodological simulation study on informative censoring in cancer clinical trials. While it involves oncology, human data, randomized trial designs, and a Phase III context, it is not an original report of a clinical trial with a drug intervention and a time-to-event efficacy endpoint. It is a research article analyzing bias, not presenting trial results.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Proteomic changes upon treatment with semaglutide in individuals with obesity. PMID 39753963 · Nat Med · 2025-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -